Top25-SA-Banner
Citron Research

About the Author Citron Research

Citron Research has been publishing columns for over 11 years, making it one of the longest-running online stock commentary websites. With over 150 reports, Citron has amassed a track record identifying fraud and terminal business models second to none among any published source. The goal of this website is and has always been to provide truthful information in an entertaining format to the investing public. Our goal has never been to engage in “gotcha” journalism. Readers are always encouraged to consider this and all information available regarding any potential investments, to seek professional assistance as necessary, and to draw their own conclusions.

Here’s Why Aphria (APHA) Stock Can Easily Rise 40% by the End of the Year


In a dramatic change, Trump announced on Friday that marijuana reform ally Mick Mulvaney will replace marijuana opponent John Kelly as his acting White House chief of staff.

Governor Andrew Cuomo outlined a plan last week to legalize marijuana in New York (a $3.1B market). The current “political atmosphere” is “unlike anything we’ve ever seen before.” With federal legalization faintly visible at the end of the tunnel, every large CPG player is now required to explain its cannabis strategy to investors.

However, the key news for Aphria (APHA) shareholders came in one-line last week in the NYT:

“Big companies are unlikely to make major moves in the American market until recreational use of THC products is legal at a federal level” (source)

Despite the increasing number of States moving towards legalization, marijuana remains a Schedule I drug at the U.S. federal level (which is why only Canadian cannabis companies are listed on the NYSE/Nasdaq).

Constellation’s investment in Canopy earlier this year was initially met with broad investor criticism that it was a one-time deal. Then, two weeks ago, Altria/Cronos announced a deal which proved that these types of partnerships have become the new standard.

The main takeaway from Cronos take-out is both i) CPG interest in cannabis is here to stay, and ii) the only way to play is through the Canadian LPs. Fact: no US companies have secured big CPG.

Even though federal legalization is around the corner, it will still take at least 18-24 months for the law to change which makes the Canadian Cannabis LPs the only game in town in the near-term. In this environment, traditional metrics can no longer be used to value the businesses of the big five Canadian Cannabis companies.

First Constellation, then Altria…this list exploring partnerships is growing by the day.

Next Up – Aphria

Shareholders of Aphria were torpedoed by a short report that questioned the corporate governance and quality of acquisitions. Although the report was well researched, the eulogy that the short sellers were writing on Aphria had to get put on hold as the dynamics of the whole industry have just changed.

Tilray, Aurora, and Aphria are the only remaining US listed Canadian LP’s that have yet to announce a major CPG partnership. Tilray’s valuation is still in the stratosphere, with Aurora’s not too far behind.

It is reasonable to assume that Cronos beat out its competitors to securing Altria because it was ‘cheaper’. Shifting gears ever so slightly, with Aphria’s recent share price decline, it is the clear winner in the ‘don’t overspend’ game. This is a look at valuations in the new landscape.

It is important to note that Aphria checks all the boxes to be a platform. It has growing operations, distribution, international, and R&D. To any of the critics who think this is any different than Cronos (if you exclude management issues — which can be easily rectified) – you are ill informed.

Aside from deals like we saw last week in Paraguay, Aphria has formed partnerships globally that are now being coveted by the larger CPG companies.

Altria’s Investment in Cronos Highlights Aphria’s Valuation Disconnect

Scarcity value will likely push the valuations of the remaining large Canadian LP’s higher.

Altria’s investment in Cronos further underpins valuation. With the Constellation and Altria’s investments, we’ve now seen two multi-billion-dollar investments at premiums of greater than 40% in each case.

Aphria generated 4x the revenue of Cronos in the last twelve months, Altria bought a 45% stake in Cronos for US$1.8 billion, and the EV of Aphria today is US$1.2 billion.

Aphria has generated US$35 million revenue in the LTM, which is in-line with what MedReleaf generated prior to being acquired by Aurora for US$2.5 billion. MedReleaf’s takeout multiple would imply a value of US$11 per share for Aphria.

Southern Glazer’s relationship is best in industry to learn the platform

Aphria has an exclusive distribution agreement with Southern Glazer’s (formerly Southern Wine and Spirits), the largest spirit distributor in North America. If one of the larger beverage companies wants to see how Cannabis might play out on a global recreational level, this one particular partnership might be worth the value of the whole company.

Could the deal be Diageo?

With a market cap of more than 2x Constellation, Chairman Javier Ferran publicly stated several months ago that he is watching the cannabis business “very closely.”

Last week, Constellation received analyst praise for its investment in Canopy. Diageo must be feeling the pressure to make a strategic move in the cannabis space.

***Citron comments that the only metric now is scarcity. If a deal were to be struck with let’s say Canntrust by a US Co, that would only make APHA more valuable as that would take one more player out of contention.

The Wildcard… Aphria gets acquired by either: Canopy, Tilray, or Aurora.

In what would be the most Machiavellian move in the cannabis space to date, a total acquisition of Aphria by its competitors would serve everyone’s needs. It’s all about the platform.

Tilray would gain a real business to justify its overvalued stock price, replace current Aphria management immediately, and remove a major competitor from the market.

Aurora has a history of buying revenue/growth and Aphria would offer that at a severe discount.

A deal for either Tilray or Aurora would increase their chances of attaining the next platform investment from a major CPG/strategic.

Canopy would get the extra capacity and the expertise in farming that is well needed, especially with one crop failure after another.

The Elephant in The Room – The Short Report

By no means is Citron discounting the quality of research done by Hindenburg Research and Quintessential, as both of those firms know we have great respect for their work.

However, instead of issuing a quick response dismissing the shorts (which, in Citron’s experience, is what the typical stock promoters do), the company is conducting an investigation led by John M. Herhalt, an independent director to Aphria who was the Global Chair of the Government & Infrastructure Practice at KPMG LLP. Seems to Citron like someone is advising Aphria and the steps taken are those that a serious industry player would take.

While we look forward to the results of the investigation, we find them irrelevant now to the greater story. Moreover, despite the questions surrounding the behavior of the Company’s CEO, Aphria has a strong and experienced management team with CPG industry background and none of them have resigned amidst the current controversy. Think about this:

Jakob Ripshtein, the President of Aphria, was previously President of Diageo Canada and CFO of Diageo North America, the company’s largest geographic region. In addition, Tom Looney joined Aphria’s board last month after retiring as President of Diageo’s US and Canadian spirits business.

Neither of these gentlemen has resigned.

Based on our estimates, we believe the strike price of Mr. Ripshtein’s options are more than 80% higher than current stock price levels. His decision to stay with the company speaks volumes.

Joel Toguri is the VP of sales of Aphria. His previous role was VP of Sales at Southern Glazer’s. He remains at Aphria despite the controversy.

Analyst Ratings

When it comes to Wall Street’s bet, the odds are on this medical marijuana maker, with TipRanks analytics showcasing APHA as a Buy. Out of 11 analysts polled in the last 3 months, 9 are bullish on Aphria stock while only 1 is sidelined and 1 is bearish. With a return potential of nearly 147%, the stock’s consensus target price stands at $14.50. (See APHA’s price targets and analyst ratings on TipRanks)

Conclusion

Despite Aphria’s strong growing operations, its association with nefarious characters has put a discount on the stock that is now too great to ignore. Citron believes that the next two weeks are the most important in Aphria’s short history and that its board will do all that it can to regain investor confidence.

In the end, Aphria has a shot at increased value through becoming the next platform company or being taken out entirely (and solving others’ problems). The stock can easily rise 40% from here by the end of the year.

Investors must acknowledge when things change. Citron admits we did not see the Cronos deal coming, but now there is only one obvious question left: Who is next?

 

From Our Partners